Investing in a startup does not make you an entrepreneur any more than buying a grand piano makes you a concert pianist.” ? Jeffrey Fry
Today we revisit Stemline Therapeutics (STML), a member of the 20-stock Busted IPO Forum model portfolio. The stock jumped over 15% last week on a litany of analyst buy recommendations. What's ahead for Stemline going forward? We explore that question in the paragraphs below.
Company Overview:
Stemline Therapeutics is a New York-based clinical stage biotech company developing oncology therapeutics. The stock came public in 2013. It currently